Tonic mGluR5/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin

Journal of Physiology

Volumn 591, Issue 4, 2013, Pages 1145-1166

  Dvorzhak, Anton ^a   Semtner, Marcus ^a   Faber, Donald S ^b   Grantyn, Rosemarie ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN FUNCTION; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; EVOKED RESPONSE; GABAERGIC TRANSMISSION; GABAERGIC UNITARY EVOKED RESPONSE; HIGH FREQUENCY STIMULATION; HOMEOSTASIS; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL INHIBITION; NERVE POTENTIAL; NERVE STIMULATION; NONHUMAN; PAIRED PULSE TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRIATAL OUTPUT NEURON; SYNAPTIC INHIBITION; SYNAPTIC POTENTIAL; UPREGULATION; WILD TYPE;

ANIMALS; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; HUNTINGTON DISEASE; MEMBRANE POTENTIALS; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84873732855     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.241018     Document Type: Article

References (72)

1. Ade KK, Janssen MJ, Ortinski PI & Vicini S (2008). Differential tonic GABA conductances in striatal medium spiny neurons. J Neurosci 28, 1185-1197.
2. Adermark L & Lovinger DM (2007). Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proc Natl Acad Sci U S A 104, 20564-20569.
3. Alger BE (2012). Endocannabinoids at the synapse a decade after the dies mirabilis (29 March 2001): what we still do not know. J Physiol 590, 2203-2212.
4. Azdad K, Chàvez M, Don BP, Wetzelaer P, Marescau B, De Deyn PP, Gall D & Schiffmann SN (2009). Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS One 4, e6908.
5. Bosch C, Mailly P, Degos B, Deniau JM & Venance L (2012). Preservation of the hyperdirect pathway of basal ganglia in a rodent brain slice. Neuroscience 215, 31-41.
6. Centonze D, Rossi S, Prosperetti C, Gasperi V, De Chiara V, Bari M, Tscherter A, Febbraro F, Bernardi G & Maccarrone M (2007). Endocannabinoids limit metabotropic glutamate 5 receptor-mediated synaptic inhibition of striatal principal neurons. Mol Cell Neurosci 35, 302-310.
7. Centonze D, Rossi S, Prosperetti C, Tscherter A, Bernardi G, Maccarrone M & Calabresi P (2005). Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol Psychiatry 57, 1583-1589.
8. Cepeda C, Ariano MA, Calvert CR, Flores-Hernández J, Chandler SH, Leavitt BR, Hayden MR & Levine MS (2001). NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66, 525-539.
9. Cepeda C, Cummings DM, André VM, Holley SM & Levine MS (2010). Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro 2, e00033.
10. Cepeda C, Starling AJ, Wu N, Nguyen OK, Uzgil B, Soda T, Andre VM, Ariano MA & Levine MS (2004). Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 78, 855-867.
11. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP & Young AB (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A 95, 6480-6485.
12. Chevaleyre V & Castillo PE (2003). Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38, 461-472.
13. Ciccarelli R, Sureda FX, Casabona G, Di Iorio P, Caruso A, Spinella F, Condorelli DF, Nicoletti F & Caciagli F (1997). Opposite influence of the metabotropic glutamate receptor subtypes mGlu3 and -5 on astrocyte proliferation in culture. Glia 21, 390-398.
14. Cummings DM, André VM, Uzgil BO, Gee SM, Fisher YE, Cepeda C & Levine MS (2009). Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 29, 10371-10386.
15. Denovan-Wright EM & Robertson HA (2000). Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705-713.
16. Estrada-Sánchez AM, Montiel T, Segovia J & Massieu L (2009). Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 34, 78-86.
17. Freiman I, Anton A, Monyer H, Urbanski MJ & Szabo B (2006). Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. J Physiol 575, 789-806.
18. Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, De Mey J, MacDonald ME, Lessmann V, Humbert S & Saudou F (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138.
19. Gertler TS, Chan CS & Surmeier DJ (2008). Dichotomous anatomical properties of adult striatal medium spiny neurons. J Neurosci 28, 10814-10824.
20. Grantyn R, Henneberger C, Jüttner R, Meier JC & Kirischuk S (2011). Functional hallmarks of GABAergic synapse maturation and the diverse roles of neurotrophins. Front Cell Neurosci 5, 13.
21. Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, Heintz N & Yang XW (2005). Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46, 433-444.
22. Hackam AS, Singaraja R, Wellington CL, Metzler M, McCutcheon K, Zhang T, Kalchman M & Hayden MR (1998). The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 141, 1097-1105.
23. Henneberger C, Kirischuk S & Grantyn R (2005). Brain-derived neurotrophic factor modulates GABAergic synaptic transmission by enhancing presynaptic glutamic acid decarboxylase 65 levels, promoting asynchronous release and reducing the number of activated postsynaptic receptors. Neuroscience 135, 749-763.
24. Henneberger C, Redman SJ & Grantyn R (2007). Cortical efferent control of subcortical sensory neurons by synaptic disinhibition. Cereb Cortex 17, 2039-2049.
25. Johnson MA, Rajan V, Miller CE & Wightman RM (2006). Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J Neurochem 97, 737-746.
26. Kirischuk S, Clements JD & Grantyn R (2002). Presynaptic and postsynaptic mechanisms underlie paired pulse depression at single GABAergic boutons. J Physiol 543, 99-116.
27. Kirischuk S, Jüttner R & Grantyn R (2005). Time-matched pre- and postsynaptic changes of GABAergic synaptic transmission in the developing mouse superior colliculus. J Physiol 563, 795-807.
28. Kirmse K, Kirischuk S & Grantyn R (2008). Activity of the GABA transporter 1 regulates GABAergic synaptic transmission in striatal projection neurons. J Physiol 586, 5665-5678.
29. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF & Levine MS (2001). Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86, 2667-2677.
30. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA & Sperlágh B (2005). Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25, 2874-2884.
31. Koos T & Tepper JM (1999). Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2, 467-472.
32. Kremer B, Squitieri F, Telenius H, Andrew SE, Theilmann J, Spence N, Goldberg YP & Hayden MR (1993). Molecular analysis of late onset Huntington's disease. J Med Genet 30, 991-995.
33. Kuwajima M, Dehoff MH, Furuichi T, Worley PF, Hall RA & Smith Y (2007). Localization and expression of group I metabotropic glutamate receptors in the mouse striatum, globus pallidus, and subthalamic nucleus: regulatory effects of MPTP treatment and constitutive Homer deletion. J Neurosci 27, 6249-6260.
34. Levine MS, Cepeda C, Hickey MA, Fleming SM & Chesselet MF (2004). Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci 27, 691-697.
35. Li XJ & Li S (2011). Proteasomal dysfunction in aging and Huntington disease. Neurobiol Dis 43, 4-8.
36. Liévens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L & Bates GP (2001). Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 8, 807-821.
37. Lu XH (2009) BAC to degeneration bacterial artificial chromosome (BAC)-mediated transgenesis for modeling basal ganglia neurodegenerative disorders. Int Rev Neurobiol 89, 37-56.
38. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW & Bates GP (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
39. Menalled L, El Khodor BF, Patry M, Suárez-Fariñas M, Orenstein SJ, Zahasky B, Leahy C, Wheeler V, Yang XW, MacDonald M, Morton AJ, Bates G, Leeds J, Park L, Howland D, Signer E, Tobin A & Brunner D (2009). Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol Dis 35, 319-336.
40. Menalled LB (2005). Knock-in mouse models of Huntington's disease. NeuroRx 2, 465-470.
41. Menalled LB, Sison JD, Dragatsis I, Zeitlin S & Chesselet MF (2003). Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465, 11-26.
42. Miller BR, Walker AG, Barton SJ & Rebec GV (2011). Dysregulated neuronal activity patterns implicate corticostriatal circuit dysfunction in multiple rodent models of Huntington's disease. Front Syst Neurosci 5, 26.
43. Milnerwood AJ, Cummings DM, Dallérac GM, Brown JY, Vatsavayai SC, Hirst MC, Rezaie P & Murphy KP (2006). Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet 15, 1690-1703.
44. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH & Raymond LA (2010). Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65, 178-190.
45. Morfini GA, You YM, Pollema SL, Kaminska A, Liu K, Yoshioka K, Björkblom B, Coffey ET, Bagnato C, Han D, Huang CF, Banker G, Pigino G & Brady ST (2009). Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci 12, 864-871.
46. Narushima M, Uchigashima M, Fukaya M, Matsui M, Manabe T, Hashimoto K, Watanabe M & Kano M (2007). Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. J Neurosci 27, 496-506.
47. Narushima M, Uchigashima M, Hashimoto K, Watanabe M & Kano M (2006). Depolarization-induced suppression of inhibition mediated by endocannabinoids at synapses from fast-spiking interneurons to medium spiny neurons in the striatum. Eur J Neurosci 24, 2246-2252.
48. Navarrete M & Araque A (2010). Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron 68, 113-126.
49. Paxinos G & Franklin KBJ (2012). The Mouse Brain in Stereotaxic Coordinates Academic Press, London.
50. + currents through a cAMP-dependent protein kinase A-independent mechanism. Neurosci 167, 678-690.
51. Romano C, Sesma MA, McDonald CT, O'Malley K, van den Pol AN & Olney JW (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol 355, 455-469.
52. Ross CA & Tabrizi SJ (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10, 83-98.
53. Rozas JL, Gómez-Sánchez L, Tomás-Zapico C, Lucas JJ & Fernández-Chacón R (2010). Presynaptic dysfunction in Huntington's disease. Biochem Soc Trans 38, 488-492.
54. Sakaba T, Schneggenburger R & Neher E (2002). Estimation of quantal parameters at the calyx of Held synapse. Neurosci Res 44, 343-356.
55. A currents. Neuroscience 167, 644-655.
56. Schneggenburger R, Sakaba T & Neher E (2002). Vesicle pools and short-term synaptic depression: lessons from a large synapse. Trends Neurosci 25, 206-212.
57. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA & Reddy PH (2011). Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 20, 1438-1455.
58. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS & Shaw DJ (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4, 393-397.
59. Surmeier DJ, Ding J, Day M, Wang Z & Shen W (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30, 228-235.
60. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 102, 2602-2607.
61. Taverna S, Ilijic E & Surmeier DJ (2008). Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci 28, 5504-5512.
62. Tecuapetla F, Koos T, Tepper JM, Kabbani N & Yeckel MF (2009). Differential dopaminergic modulation of neostriatal synaptic connections of striatopallidal axon collaterals. J Neurosci 29, 8977-8990.
63. Tepper JM & Bolam JP (2004). Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol 14, 685-692.
64. Tepper JM, Wilson CJ & Koos T (2008). Feedforward and feedback inhibition in neostriatal GABAergic spiny neurons. Brain Res Rev 58, 272-281.
65. The Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded an unstable on Huntington's disease chromosomes. Cell 72, 971-983.
66. Tobin AJ & Signer ER (2000). Huntington's disease: the challenge for cell biologists. Trends Cell Biol 10, 531-536.
67. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE & McMurray CT (2006). Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 15, 3578-3591.
68. Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR & Hayden MR (2005). Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet 14, 3823-3835.
69. Venance L, Piomelli D, Glowinski J & Giaume C (1995). Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376, 590-594.
70. Walter L, Dinh T & Stella N (2004). ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. J Neurosci 24, 8068-8074.
71. Yrjanheikki JM, Puoliväli J, Lehtimäki K, Park LC, Howland D, Kontkanen O & Heikkinen T (2011). Characterization of behavioral changes, MRI brain volumetry and MRI spectroscopy in q175 knock in mouse model of Huntington's disease. Society for Neuroscience Abstracts.
72. Zuccato C & Cattaneo E (2009). Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5, 311-322.